| Lysosomes as mediators of drug resistance in cancer B Zhitomirsky, YG Assaraf Drug Resistance Updates 24, 23-33, 2016 | 408 | 2016 |
| Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance B Zhitomirsky, YG Assaraf Oncotarget 6 (2), 1143, 2015 | 225 | 2015 |
| Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis B Zhitomirsky, YG Assaraf Oncotarget 8 (28), 45117, 2017 | 139 | 2017 |
| Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity B Zhitomirsky, A Yunaev, R Kreiserman, A Kaplan, M Stark, YG Assaraf Cell death & disease 9 (12), 1191, 2018 | 104 | 2018 |
| LysoTracker and MitoTracker Red are transport substrates of P‐glycoprotein: implications for anticancer drug design evading multidrug resistance B Zhitomirsky, H Farber, YG Assaraf Journal of cellular and molecular medicine 22 (4), 2131-2141, 2018 | 70 | 2018 |
| The role of cytoplasmic-to-lysosomal pH gradient in hydrophobic weak base drug sequestration in lysosomes B Zhitomirsky, YG Assaraf Cancer Cell & Microenvironment 2 (3), 2015 | 19 | 2015 |
| The 5′ arm of Kluyveromyces lactis telomerase RNA is critical for telomerase function MM Kabaha, B Zhitomirsky, I Schwartz, Y Tzfati Molecular and cellular biology 28 (6), 1875-1882, 2008 | 19 | 2008 |
| Protein-coated corrole nanoparticles for the treatment of prostate cancer cells M Soll, QC Chen, B Zhitomirsky, PP Lim, J Termini, HB Gray, YG Assaraf, ... Cell death discovery 6 (1), 1-17, 2020 | 18 | 2020 |
| Correction: Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance B Zhitomirsky, YG Assaraf Oncotarget 13, 585, 2022 | 1 | 2022 |
